Recent Quotes (30 days)

You have no recent quotes
chg | %

AstraZeneca plc news

   Watch this stock
Showing stories 1 - 10 of about 52   

Articles published

AZN 4,477.74 +8.24 (0.18%)
price chart
AstraZeneca to Buy Back $4.5 Billion in Stock, Cut Jobs as Patents Expire
Feb. 2 (Bloomberg) -- AstraZeneca Plc, the U.K.'s second-biggest drugmaker, fell the most in five months after saying profit this year will decline as the company prepares to face generic competition to top-selling medicines.
AstraZeneca Plans to Cut 7300 Jobs  Wall Street Journal
AstraZeneca closing Montreal R&D plant  Globe and Mail
Related articles »  
Europe Job Losses Accelerate With AstraZeneca-to-PepsiCo Firing Employees
13 (Bloomberg) -- Global companies from NEC Corp. to PepsiCo Inc. and AstraZeneca Plc are chopping jobs more than three times faster than in 2011 as they brace for recession in Europe and a slowdown in China.
Related articles »  
Europe approves AstraZeneca thyroid cancer drug
Vandetanib was once seen as a potential $1 billion (630 million pound) plus blockbuster for AstraZeneca but suffered a major setback after failing to extend survival in patients with lung cancer.
Related articles »  
Making the right exit: Lessons learned from AstraZeneca and IBM
The MSA also contained an obligation on AstraZeneca to produce an IT transfer plan for IBM detailing how the services would be transferred away from IBM.
Related articles »  
AstraZeneca Loses Ruling Over 2018 and 2021 Crestor Patents
Feb. 9 (Bloomberg) -- AstraZeneca Plc lost a U.S. appeals court bid to protect its best-selling drug, Crestor, from generic competition until as late as 2021.
Related articles »  
AstraZeneca India job cuts likely to hurt drug research
New Delhi: Theextensive layoffs at London-listed drug maker AstraZeneca Plc's research outfits have hit India. On 13 February, the firm's Bangalore subsidiary laid off 19 employees�15 of them middle-level and senior scientists involved in the research ...
Related articles »  
Astra takes brand cancer drug straight to patients
(Reuters) - AstraZeneca Plc is selling breast cancer drug Arimidex directly to U.S. patients, offering an option for people who want to pay for the brand instead of generic versions.
Related articles »  
Tracing Fake Avastin to the Mideast
... health-care providers about the appearance of "non-FDA-approved injectable cancer medications" that were "most likely" administered to patients, including unauthorized versions of Roche's Herceptin and Rituxan, AstraZeneca PLC's Faslodex and Amgen ...
Related articles »  
Fakes Infiltrate Injectable Drugs
13, the FDA also alerted British drug maker AstraZeneca PLC to "a number of cases of illegal importation of oncology drugs into the U.S.
Selling Fake Drugs Is a Booming Business And Increasingly Easier  Medical Daily
Related articles »  
R&D in Quebec pharma industry continues to erode
PetroChina in shale deal China is moving ever deeper into Canada's energy industry with a deal by PetroChina Co. today to join Royal Dutch Shell PLC in a shale gas project in northeastern British Columbia. The company did not disclose the pricetag for ...
Related articles »